Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Gains from Investment Securities (2019 - 2022)

C4 Therapeutics has reported Gains from Investment Securities over the past 4 years, most recently at $44.1 million for Q1 2022.

  • For Q1 2022, Gains from Investment Securities rose 640.26% year-over-year to $44.1 million; the TTM value through Dec 2022 reached $44.1 million, changed N/A, while the annual FY2022 figure was $44.1 million, 636.48% up from the prior year.
  • Gains from Investment Securities for Q1 2022 was $44.1 million at C4 Therapeutics, up from $20.1 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $44.1 million in Q1 2022 and troughed at $1.4 million in Q2 2021.
  • A 4-year average of $10.1 million and a median of $2.8 million in 2020 define the central range for Gains from Investment Securities.
  • On a YoY basis, Gains from Investment Securities climbed as much as 694.12% in 2021 and fell as far as 48.13% in 2021.
  • Year by year, Gains from Investment Securities stood at $2.3 million in 2019, then grew by 9.7% to $2.5 million in 2020, then skyrocketed by 694.12% to $20.1 million in 2021, then skyrocketed by 118.9% to $44.1 million in 2022.
  • Business Quant data shows Gains from Investment Securities for CCCC at $44.1 million in Q1 2022, $20.1 million in Q4 2021, and $1.6 million in Q3 2021.